Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
16
Not yet recruiting, industry sponsors, Kidney and urology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed344
16 trials
Showing 1 to 16, recently updated first.
- A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated AnemiaPivotal-lookingNot yet recruiting
Kind Pharmaceuticals LLCIndustry
NCT07950215 · 240 participants (planned) · Start Feb 1, 2027 · Primary completion Dec 1, 2027
Drug: AND017 capsules; ESA · For: Anemia Due to Chronic Kidney Disease
- An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.Pivotal-lookingNot yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07951190 · 36 participants (planned) · Start Nov 16, 2026 · Primary completion Nov 25, 2032
Drug: Iptacopan · For: Complement Mediated Diseases e.g. PNH, IgAN
- Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingNot yet recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07770815 · 24 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 29, 2029
Drug: Sibeprenlimab; Standard of care · For: IgA Nephropathy
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931547 · 450 participants (planned) · Start Nov 10, 2026 · Primary completion Jul 31, 2028
Drug: Zenagamtide · For: Type 2 Diabetes; Chronic Kidney Disease
Sites: La Jolla, California; Lancaster, California; Lincoln, California · 125 sites in all
- Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. (BENIPRO)Pivotal-lookingNot yet recruiting
Eurofarma Laboratorios S.A.Industry
NCT06546735 · 816 participants (planned) · Start Nov 30, 2026 · Primary completion Apr 30, 2028
Drug: N0728; Vesomni® · For: Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Sites: São Paulo, Brazil
- A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisPivotal-lookingNot yet recruiting
Pathalys PharmaIndustry
NCT07890584 · 56 participants (planned) · Start Oct 30, 2026 · Primary completion Feb 22, 2032
Drug: PLS240 · For: Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism
Sites: Buffalo, New York
- Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic HyperplasiaPivotal-lookingNot yet recruiting
Il-Yang Pharm. Co., Ltd.Industry
NCT07870759 · 660 participants (planned) · Start Nov 9, 2026 · Primary completion Aug 31, 2027
Drug: Finasteride 5 mg Tablet, single dose; Tamsulosin 0.4Mg Capsule · For: Benign Prostatic Hyperplasia
- Non-invasive Saphenous Nerve Stimulation Therapy for Overactive BladderPivotal-lookingNot yet recruiting
NinaMED Pty LtdIndustry
NCT07780786 · 290 participants (planned) · Start Sep 10, 2026 · Primary completion Dec 10, 2027
Drug: tolterodine tartrate 4 mg extended release · For: Overactive Bladder (OAB)
Sites: Camden, New Jersey; Maribyrnong, Australia
- A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA NephropathyPivotal-lookingNot yet recruiting
Biohaven Therapeutics Ltd.Industry
NCT07642050 · 420 participants (planned) · Start Jun 2026 · Primary completion Sep 2028
Drug: BHV-1400; Placebo · For: IgA Nephropathy
- Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney DiseasePivotal-lookingNot yet recruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07625774 · 3,690 participants (planned) · Start Jul 2026 · Primary completion May 2031
Drug: HRS-7535; Placebo · For: Chronic Kidney Disease
Sites: Tianjin, China; Hangzhou, China
- A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)Pivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07300111 · 100 participants (planned) · Start Dec 31, 2025 · Primary completion May 2027
Drug: Daprodustat; Darbepoetin alfa · For: Anaemia
- Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic HyperplasiaPivotal-lookingNot yet recruiting
Ache Laboratorios Farmaceuticos S.A.Industry
NCT07270432 · 218 participants (planned) · Start Jan 2026 · Primary completion Apr 2027
Drug: Product DNN.65.21.005; Combodart® · For: Prostatic Hyperplasia, Benign
- Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease ProgressionPivotal-lookingNot yet recruiting
Ebima Clifford OkundayeIndustry
NCT06866236 · 3,000 participants (planned) · Start Oct 2025 · Primary completion Oct 2026
Drug: QRX-3 · For: Chronic Kidney Diseases; Acute Kidney Injury; Kidney Failure
Sites: Pasedena, Texas
- A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic HyperplasiaPivotal-lookingNot yet recruiting
Shanghai Huilun Pharmaceutical Co., Ltd.Industry
NCT07146386 · 728 participants (planned) · Start Aug 2025 · Primary completion Jan 2027
Drug: H077 sustained-release tablet; Silodosin capsules Control Group · For: Benign Prostatic Hyperplasia; Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Sites: Hefei, China; Beijing, China; Chongqing, China · 66 sites in all
- Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease PatientsPivotal-lookingNot yet recruiting
MegalabsIndustry
NCT06352138 · 280 participants (planned) · Start Jul 2025 · Primary completion Mar 2027
Drug: Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration.; Active comparator: European Union licenced epoetin alfa · For: Anemia of Chronic Kidney Disease
Sites: Colonia Nicolich, Uruguay
- Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic HyperplasiaPivotal-lookingNot yet recruiting
EMSIndustry
NCT06264414 · 262 participants (planned) · Start Feb 2025 · Primary completion Jun 2026
Drug: DTT106; Dutasteride-Tamsulosin · For: Prostatic Hyperplasia, Benign; Erectile Dysfunction
Sites: Hortolândia, Brazil
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.